Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors

Mostrar otras versiones (1)

Merck's MK-0518, known as raltegravir, has recently become the first FDA-approved HIV-1 integrase (IN) inhibitor and has since risen to blockbuster drug status. Much research has in turn been conducted over the last few years aimed at recreating but optimizing the compound's interactions w...

Descripción completa

Detalles Bibliográficos
Autores principales: Serrao, Erik, Odde, Srinivas, Ramkumar, Kavya, Neamati, Nouri
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2660292/
https://www.ncbi.nlm.nih.gov/pubmed/19265512
http://dx.doi.org/10.1186/1742-4690-6-25

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2660292/
https://www.ncbi.nlm.nih.gov/pubmed/19265512
http://dx.doi.org/10.1186/1742-4690-6-25

Ejemplares similares